Pharvaris N.V.
Pharvaris N.V. (PHVS) Company Profile & Overview
Explore Pharvaris N.V.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Pharvaris N.V. (PHVS) Company Profile & Overview
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.